Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The hematopoietic stem cell transplantation in Indonesia: an unsolved dilemma

Bone Marrow Transplantation volume 42, pages S85–S88 (2008)Cite this article

Abstract

Allogeneic BMT was performed in Indonesia, but had to be stopped prematurely because of the small number of patients. In the beginning, only patients with sufficient financial resources to travel to western countries could undergo transplant procedures. When neighbouring countries (Singapore and Malaysia) began performing transplant, patients were referred to those centres. In both countries, the procedure is more economical and therefore patients come from a broader range of economic classes. The Indonesian hematologist must deal with the post-transplantation side effects, such as GVHD, which are mostly of the chronic type of GVHD. The types of the post-transplant complications do not differ too much from other centres and need the same treatment used in the transplant centres. Hematologists in Indonesia also treat complications of HSCT performed in other countries. When there is no recovery of HSCT development in Indonesia so far, many commercially oriented companies or centres from other countries see Indonesia as a good commercial market and offer services, some of which are not scientifically sound. One of the main problems is umbilical cord blood stem cell banking from foreign countries, which is eagerly offered to parents expecting a baby. Moreover, parents are not fully protected by law. In conclusion, Indonesia needs to revive its own HSCT program to serve and protect its own patients of being used as commercial targets by other countries.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Champlin R, Khouri I, Kornblau S, Molldrem J, Giralt S . Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol 1999; 11: 87–95.

    Article  CAS  Google Scholar 

  2. Bai L, Chiou T, Liu J, Yen C, Wang WS, Yan MH et al. Hematopoietic stem cell transplantation for severe aplastic anemia-experience of an institute in Taiwan Annals of Hematology. Ann Hematol 2004; 83: 38–43.

    Article  CAS  Google Scholar 

  3. Tan P, Ong YW, Goh YT, Lim SH, Ng HW . Allogeneic bone marrow transplantation for acute non-lymphoblastic leukaemia—the Singapore experience. Ann Acad Med Singapore 1990; 19: 161–168.

    CAS  PubMed  Google Scholar 

  4. Ariffin H, Chen SP, Kwok CS, Quah TC, Lin HP, Yeoh AE . Ethnic differences in the frequency of subtypes of childhood acute lymphoblastic leukemia: results of the Malaysia-Singapore Leukemia Study Group. J Pediatr Hematol/Oncol 2007; 29: 27–31.

    Article  Google Scholar 

  5. Pavletic SZ, Lee SJ, Socie G, Vogelsang G . Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. Bone Marrow Transplant 2006; 38: 645–651.

    Article  CAS  Google Scholar 

  6. Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY et al. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy. Biol Blood Marrow Transplant 2007; 13: 790–805.

    Article  CAS  Google Scholar 

  7. Loh YS, Koh LP, Tai BC, Hwang WY, Linn YC, Goh YT et al. Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs autologous hematopoietic stem cell transplantation. Leuk Lymphoma 2007; 48: 72–79.

    Article  Google Scholar 

  8. Loh SM, Ratnagopal P, Tan HC, Goh YT, Koh BC, Koh LP et al. Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning. Int J Hematol 2006; 83: 368–369.

    Article  Google Scholar 

  9. Tan PH, Hwang WY, Goh YT, Tan PL, Koh LP, Tan CH et al. Unrelated peripheral blood and cord blood hematopoietic stem cell transplants for thalassemia major. Am J Hematol 2004; 75: 209–212.

    Article  Google Scholar 

  10. Tan PL, Shek PC, Lim LC, How GF, Tan P, Yeoh AE et al. Umibilical cord blood stem cell from unrelated donors is a feasible alternate stem cell source for transplant in patients with genetic diseases. Ann Acad Med Singapore 2004; 33 (5 Suppl): S82–S83.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology (Clinical Pathology), School of Medicine, University of North Sumatera/Haj. Adam Malik Hospital, Medan, Indonesia

    H Hariman

Authors
  1. H Hariman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Hariman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hariman, H. The hematopoietic stem cell transplantation in Indonesia: an unsolved dilemma. Bone Marrow Transplant 42 (Suppl 1), S85–S88 (2008). https://doi.org/10.1038/bmt.2008.125

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.125

Keywords

This article is cited by

Search

Advanced search

Quick links